Changes in gut microbiota and lactose intolerance symptoms before and after daily lactose supplementation in individuals with the lactase nonpersistent genotype

• Published in: The American journal of clinical nutrition 2024-03, Vol.119 (3), p.702-710
• Main Authors: JanssenDuijghuijsen, Lonneke, Looijesteijn, Ellen, van den Belt, Maartje, Gerhard, Beatrix, Ziegler, Martin, Ariens, Renata, Tjoelker, Reina, Geurts, Jan
• Format: Article
• Language: English
• Subjects: Adaptation; Adult; beta-Galactosidase - genetics; beta-Galactosidase - therapeutic use; bifidobacteria; Bifidobacterium; Breath Tests; clinical trial; Dietary Supplements; Digestive system; fecal β-galactosidase activity; Feces; Galactosidase; Gas formation; Gas production; Gastrointestinal Microbiome; Gastrointestinal symptoms; Gastrointestinal tract; Genotype; Genotype & phenotype; Genotypes; gut microbial adaptation; Humans; Hydrogen; Hydrogen - therapeutic use; hydrogen breath test; Intervention; Intestinal microflora; Intolerance; Lactase; Lactase - genetics; lactase nonpersistence; Lactose; Lactose - metabolism; lactose intolerance; Lactose Intolerance - genetics; Microbiota; Microorganisms; Oil and gas production; Relative abundance; β-Galactosidase
• ISSN: 0002-9165; 1938-3207; 1938-3207
• DOI: 10.1016/j.ajcnut.2023.12.016

Approximately 70%–100% of the Asian adult population is lactase nonpersistent (LNP). The literature shows that many individuals with the LNP-genotype can consume ≤12 g of lactose without experiencing gastrointestinal discomfort. Repetitive consumption of lactose may reduce intolerance symptoms via adaptation of the gut microbiota. This study aimed to assess the effects of daily consumption of incremental lactose doses on microbiota composition and function, and intolerance symptoms. Twenty-five healthy adults of Asian origin, carrying the LNP-genotype were included in this 12-wk before and after intervention trial. Participants consumed gradually increasing lactose doses from 3 to 6 g to 12 g twice daily, each daily dose of 6 g, 12 g, or 24 g being provided for 4 consecutive weeks. Participants handed-in repeated stool samples and underwent a 25 g lactose challenge hydrogen breath test (HBT) before and after the 12-wk intervention. Daily gastrointestinal symptoms and total symptom scores (TSSs) during the lactose challenge were recorded. A significant increase from 5.5% ± 7.6% to 10.4% ± 9.6% was observed in Bifidobacterium relative abundance after the intervention (P = 0.009), accompanied by a 2-fold increase (570 ± 269 U/g; P < 0.001) in fecal β-galactosidase activity compared with baseline (272 ± 158 U/g). A 1.5-fold decrease (incremental area under the curve; P = 0.01) in expired hydrogen was observed during the second HBT (38 ± 35 ppm·min), compared with the baseline HBT (57 ± 38 ppm·min). There was a nonsignificant decrease in TSS (10.6 ± 8.3 before compared with 8.1 ± 7.2 after intervention; P = 0.09). Daily consumption of lactose was well tolerated, with mild to no gastrointestinal complaints reported during the intervention. Increased levels of Bifidobacterium indicate an adaptation of the gut microbiota upon repetitive consumption of incremental doses of lactose, which was well tolerated as demonstrated by reduced expired hydrogen concentrations during the second 25-g lactose HBT. Bifidobacteria metabolize lactose without gas production thereby potentially reducing intestinal gas formation in the gut of individuals with the LNP-genotype. This increased lactose tolerance possibly lifts the necessity to remove nutrient-rich dairy foods completely from the diet. The trial is registered at the International Clinical Trials Registry Platform: NL9516. The effect of dietary lactose in lactase nonpersistent individuals on gut microbiota.